Covalent inhibitors of interleukin-2 inducible T cell kinase (ItK) with nanomolar potency in a whole-blood assay

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 10047-10063

  Zapf, Christoph W ^a   Gerstenberger, Brian S ^a   Xing, Li ^a   Limburg, David C ^a   Anderson, David R ^a   Caspers, Nicole ^a   Han, Seungil ^a   Aulabaugh, Ann ^a   Kurumbail, Ravi ^a   Shakya, Subarna ^a   Li, Xin ^a   Spaulding, Vikki ^a   Czerwinski, Robert M ^a   Seth, Nilufer ^a   Medley, Quintus G ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; INTERLEUKIN 2 INDUCIBLE T CELL KINASE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; T LYMPHOCYTE; WHOLE BLOOD ASSAY;

DRUG DESIGN; HALF-LIFE; HUMANS; INTERLEUKIN-2; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, T-CELL; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 84870005710     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301190s     Document Type: Article

References (44)

1. Iyer, A. S.; August, A. The Tec family kinase, IL-2-inducible T cell kinase, differentially controls mast cell responses J. Immunol. 2008, 180, 7869-7877
2. Andreotti, A. H.; Schwartzberg, P. L.; Joseph, R. E.; Berg, L. J. T-cell signaling regulated by the Tec family kinase, Itk Cold Spring Harbor Perspect. Biol. 2010, 2, a002287
3. Berg, L. J.; Finkelstein, L. D.; Lucas, J. A.; Schwartzberg, P. L. Tec family kinases in T lymphocyte development and function Annu. Rev. Immunol. 2005, 23, 549-600
4. Burbach, B. J.; Medeiros, R. B.; Mueller, K. L.; Shimizu, Y. T-cell receptor signaling to integrins Immunol. Rev. 2007, 218, 65-81
5. Sahu, N.; Mueller, C.; Fischer, A.; August, A. Differential sensitivity to Itk kinase signals for T helper 2 cytokine production and chemokine-mediated migration J. Immunol. 2008, 180, 3833-3838
6. Kosaka, Y.; Felices, M.; Berg, L. J. Itk and Th2 responses: action but no reaction Trends Immunol. 2006, 27, 453-460
7. Au-Yeung, B. B.; Katzman, S. D.; Fowell, D. J. Cutting edge: Itk-dependent signals required for CD4+ T cells to exert, but not gain, Th2 effector function J. Immunol. 2006, 176, 3895-3899
8. Gomez-Rodriguez, J.; Sahu, N.; Handon, R.; Davidson, T. S.; Anderson, S. M.; Kirby, M. R.; August, A.; Schwartzberg, P. L. Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase Immunity 2009, 31, 587-597
9. Takesono, A.; Horai, R.; Mandai, M.; Dombroski, D.; Schwartzberg, P. L. Requirement for Tec kinases in chemokine-induced migration and activation of Cdc42 and Rac Curr. Biol. 2004, 14, 917-922
10. Fischer, A. M.; Mercer, J. C.; Iyer, A.; Ragin, M. J.; August, A. Regulation of CXC chemokine receptor 4-mediated migration by the Tec family tyrosine kinase ITK J. Biol. Chem. 2004, 279, 29816-29820
11. Readinger, J. A.; Schiralli, G. M.; Jiang, J. K.; Thomas, C. J.; August, A.; Henderson, A. J.; Schwartzberg, P. L. Selective targeting of ITK blocks multiple steps of HIV replication Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 6684-6689
12. Lin, T. A.; McIntyre, K. W.; Das, J.; Liu, C.; O'Day, K. D.; Penhallow, B.; Hung, C. Y.; Whitney, G. S.; Shuster, D. J.; Yang, X.; Townsend, R.; Postelnek, J.; Spergel, S. H.; Lin, J.; Moquin, R. V.; Furch, J. A.; Kamath, A. V.; Zhang, H.; Marathe, P. H.; Perez-Villar, J. J.; Doweyko, A.; Killar, L.; Dodd, J. H.; Barrish, J. C.; Wityak, J.; Kanner, S. B. Selective Itk inhibitors block T-cell activation and murine lung inflammation Biochemistry 2004, 43, 11056-11062
13. Das, J.; Furch, J. A.; Liu, C.; Moquin, R. V.; Lin, J.; Spergel, S. H.; McIntyre, K. W.; Shuster, D. J.; O'Day, K. D.; Penhallow, B.; Hung, C. Y.; Doweyko, A. M.; Kamath, A.; Zhang, H.; Marathe, P.; Kanner, S. B.; Lin, T. A.; Dodd, J. H.; Barrish, J. C.; Wityak, J. Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 3706-3712
14. Kashem, M. A.; Nelson, R. M.; Yingling, J. D.; Pullen, S. S.; Prokopowicz, A. S., 3rd; Jones, J. W.; Wolak, J. P.; Rogers, G. R.; Morelock, M. M.; Snow, R. J.; Homon, C. A.; Jakes, S. Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors J. Biomol. Screening 2007, 12, 70-83
15. Winters, M. P.; Robinson, D. J.; Khine, H. H.; Pullen, S. S.; Woska, J. R., Jr.; Raymond, E. L.; Sellati, R.; Cywin, C. L.; Snow, R. J.; Kashem, M. A.; Wolak, J. P.; King, J.; Kaplita, P. V.; Liu, L. H.; Farrell, T. M.; DesJarlais, R.; Roth, G. P.; Takahashi, H.; Moriarty, K. J. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk) Bioorg. Med. Chem. Lett. 2008, 18, 5541-5544
16. Snow, R. J.; Abeywardane, A.; Campbell, S.; Lord, J.; Kashem, M. A.; Khine, H. H.; King, J.; Kowalski, J. A.; Pullen, S. S.; Roma, T.; Roth, G. P.; Sarko, C. R.; Wilson, N. S.; Winters, M. P.; Wolak, J. P.; Cywin, C. L. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 3660-3665
17. Moriarty, K. J.; Takahashi, H.; Pullen, S. S.; Khine, H. H.; Sallati, R. H.; Raymond, E. L.; Woska, J. R., Jr.; Jeanfavre, D. D.; Roth, G. P.; Winters, M. P.; Qiao, L.; Ryan, D.; DesJarlais, R.; Robinson, D.; Wilson, M.; Bobko, M.; Cook, B. N.; Lo, H. Y.; Nemoto, P. A.; Kashem, M. A.; Wolak, J. P.; White, A.; Magolda, R. L.; Tomczuk, B. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk) Bioorg. Med. Chem. Lett. 2008, 18, 5545-5549
18. Cook, B. N.; Bentzien, J.; White, A.; Nemoto, P. A.; Wang, J.; Man, C. C.; Soleymanzadeh, F.; Khine, H. H.; Kashem, M. A.; Kugler, S. Z., Jr.; Wolak, J. P.; Roth, G. P.; De Lombaert, S.; Pullen, S. S.; Takahashi, H. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design Bioorg. Med. Chem. Lett. 2009, 19, 773-777
19. Riether, D.; Zindell, R.; Kowalski, J. A.; Cook, B. N.; Bentzien, J.; Lombaert, S. D.; Thomson, D.; Kugler, S. Z., Jr.; Skow, D.; Martin, L. S.; Raymond, E. L.; Khine, H. H.; O'Shea, K.; Woska, J. R., Jr.; Jeanfavre, D.; Sellati, R.; Ralph, K. L.; Ahlberg, J.; Labissiere, G.; Kashem, M. A.; Pullen, S. S.; Takahashi, H. 5-Aminomethylbenzimidazoles as potent ITK antagonists Bioorg. Med. Chem. Lett. 2009, 19, 1588-1591
20. Charrier, J. D.; Miller, A.; Kay, D. P.; Brenchley, G.; Twin, H. C.; Collier, P. N.; Ramaya, S.; Keily, S. B.; Durrant, S. J.; Knegtel, R. M.; Tanner, A. J.; Brown, K.; Curnock, A. P.; Jimenez, J. M. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors J. Med. Chem. 2011, 54, 2341-2350
21. Knegtel, R. M. A.; Robinson, D. D. A Role for Hydration in interleukin-2 inducible T cell kinase (Itk) selectivity Mol. Inf. 2011, 30, 950-959
22. Flynn, G. A.; Lee, S. A.; Faris, M.; Brandt, D. W.; Chakravarty, S. Intracellular Kinase Inhibitors. US 2007/0293499 A1, 2007.
23. Alder, C. M.; Baldwin, I. R.; Barton, N. P.; Campbell, A. J.; Champigny, A. C.; Harling, J. D.; Maxwell, A. C. Derivatives of 2-[2-(Benzo- or Pyrido-)thiazolylamino]-6-aminopyridine, Useful in the Treatment of Respiratoric, Allergic or Inflammatory Diseases. WO 2011/110575 Al, 2011.
24. Maxwell, A. C.; Alder, C.; Ambler, M.; Campbell, A.; Champigny, A.; Harling, J.; Scullion, C.; Smith, I.; Somers, D.; Tame, C.; Wilson, C.; Woolven, J. In Identification of Novel and Selective ITK Inhibitors through a Template Hopping Strategy; American Chemical Society: Washington, DC, 2011; pp MEDI-8.
25. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
26. Swinney, D. C. Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discovery 2004, 3, 801-808
27. Bogoyevitch, M. A.; Fairlie, D. P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding Drug Discovery Today 2007, 12, 622-633
28. Harrison, S.; Das, K.; Karim, F.; Maclean, D.; Mendel, D. Non-ATP-competitive kinase inhibitors: enhancing selectivity through new inhibition strategies Expert Opin. Drug Discovery 2008, 3, 761-774
29. Navratilova, I.; Macdonald, G.; Robinson, C.; Hughes, S.; Mathias, J.; Phillips, C.; Cook, A. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action J. Biomol. Screening 2012, 17, 183-193
30. Han, S. Unpublished results.
31. Robertson, J. G. Mechanistic basis of enzyme-targeted drugs Biochemistry 2005, 44, 5561-5571
32. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Nat. Rev. Drug Discovery 2011, 10, 307-317
33. Schwobel, J. A.; Koleva, Y. K.; Enoch, S. J.; Bajot, F.; Hewitt, M.; Madden, J. C.; Roberts, D. W.; Schultz, T. W.; Cronin, M. T. Measurement and estimation of electrophilic reactivity for predictive toxicology Chem. Rev. 2011, 111, 2562-2596
34. Kim, K. H.; Maderna, A.; Schnute, M. E.; Hegen, M.; Mohan, S.; Miyashiro, J.; Lin, L.; Li, E.; Keegan, S.; Lussier, J.; Wrocklage, C.; Nickerson-Nutter, C. L.; Wittwer, A. J.; Soutter, H.; Caspers, N.; Han, S.; Kurumbail, R.; Dunussi-Joannopoulos, K.; Douhan, J., 3rd; Wissner, A. Imidazo[1,5-a] quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis Bioorg. Med. Chem. Lett. 2011, 21, 6258-6263
35. Pan, Z.; Scheerens, H.; Li, S. J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase ChemMedChem 2007, 2, 58-61
36. Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 13075-13080
37. Wissner, A.; Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. (Weinheim, Ger.) 2008, 341, 465-477
38. Nakayama, S.; Atsumi, R.; Takakusa, H.; Kobayashi, Y.; Kurihara, A.; Nagai, Y.; Nakai, D.; Okazaki, O. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 2009, 37, 1970-1977
39. Naramura, M.; Band, V.; Band, H. Indispensable roles of mammalian Cbl family proteins as negative regulators of protein tyrosine kinase signaling: Insights from in vivo models Commun. Integr. Biol. 2011, 4, 159-162
40. Katkere, B.; Rosa, S.; Drake, J. R. The Syk-binding ubiquitin ligase c-Cbl mediates signaling-dependent B cell receptor ubiquitination and B cell receptor-mediated antigen processing and presentation J. Biol. Chem. 2012, 287, 16636-16644
41. Paolino, M.; Thien, C. B.; Gruber, T.; Hinterleitner, R.; Baier, G.; Langdon, W. Y.; Penninger, J. M. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions J. Immunol. 2011, 186, 2138-2147
42. Kawasaki, Y.; Freire, E. Finding a better path to drug selectivity Drug Discovery Today 2011, 16, 985-990
43. Wang, Z.; Watt, W.; Brooks, N. A.; Harris, M. S.; Urban, J.; Boatman, D.; McMillan, M.; Kahn, M.; Heinrikson, R. L.; Finzel, B. C.; Wittwer, A. J.; Blinn, J.; Kamtekar, S.; Tomasselli, A. G. Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors Biochim. Biophys. Acta 2010, 1804, 1817-1831
44. Singh, J.; Dobrusin, E. M.; Fry, D. W.; Haske, T.; Whitty, A.; McNamara, D. J. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases J. Med. Chem. 1997, 40, 1130-1135